Colonial River Investments LLC Makes New $68,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Colonial River Investments LLC acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,094 shares of the company’s stock, valued at approximately $68,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RXRX. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals during the 3rd quarter worth about $25,000. Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals during the 4th quarter worth about $26,000. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $9.00 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a 50 day simple moving average of $7.59 and a 200 day simple moving average of $7.04. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $15.74. The firm has a market capitalization of $3.52 billion, a PE ratio of -5.88 and a beta of 0.86.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.